Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combination Drug Therapy Offers Hope For Malaria Treatment

05.01.2004


Two articles and a Commentary in this week’s issue highlight how combination therapy offers the best hope for tackling drug resistance for the millions of people worldwide affected by malaria.



Drug resistance is the main barrier to effective malaria treatment. Artemisinin (extract of sweet wormwood , commonly used in Chinese herbal medicine) and its derivatives, artemether and artesunate, are of potential importance as other malarial drugs have been associated with microbial resistance.

A meta-analysis by the International Artemisinin Study Group of 16 randomised trials (12 from sub-Saharan Africa, three from Thailand, one from Peru) shows that artesunate was highly effective in treating malaria when added to other antimalarial drugs. Around 6000 patients were participants in the studies. Artesunate decreased parasite failure by around 80% and doubled the rate of parasite clearance compared with patients given standard malaria treatment.


Patrick E Duffy and Theonest K Mutabingwa consider in an accompanying Commentary (p 3) the policy implications for the use of artemisinin combination treatment (ACT) in different countries. They comment: “Will ACT reduce malaria incidence and prevent the emergence and spread of drug-resistant parasites in Africa, as occurred in southeast Asia? Only additional research will answer these questions. However, because of differences in epidemiology and intensity of transmission, reducing malaria incidence in Africa will be challenging.”

A study from Vietnam in this week’s issue (p 18) also assesses combination treatment for malaria. Tran Tinh Hien and colleagues found that the new combination dihydroartemisinin-piperaquine, formulated in a single tablet, is highly efficacious in Vietnam, where multidrug-resistant parasites are common. Authors of the Commentary state: “Dihydroartemisinin-piperaquine has a cost advantage (US$1 for an adult treatment) that brings it within reach of many but not all consumers, and encourages funding agencies to sponsor programmes that deliver these needed medicines to poorer countries.”

Richard Lane | alfa
Further information:
http://www.lancet.com

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Multifunctional Platform for the Delivery of Gene Therapeutics

22.01.2018 | Life Sciences

The world's most powerful acoustic tractor beam could pave the way for levitating humans

22.01.2018 | Power and Electrical Engineering

Siberian scientists learned how to reduce harmful emissions from HPPs

22.01.2018 | Power and Electrical Engineering

VideoLinks